Literature DB >> 22917719

A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism.

A M López-Parra1, A M Borobia, C Baeza, E Arroyo-Pardo, A J Carcas.   

Abstract

OBJECTIVES: We have developed a genotyping system to determine the alleles of genes related to interindividual variability in acenocoumarol dosage requirements. This genotyping system is intended for routine clinical use and therefore it is essential that it be simple, fast and inexpensive. DESIGN AND METHODS: We developed a PCR multiplex SNaPshot reaction that targets 6 SNPs (single nucleotide polymorphisms) in CYP2C9, CYP4F2, VKORC1 and APOE genes, which are associated with acenocoumarol dose requirements.
RESULTS: We tested the multiplex in 152 samples and found it to be 100% concordant with the results of other methods.
CONCLUSIONS: We successfully produced a reliable multiplex system for simultaneously typing 6 SNPs. This system may be used as a model for accurate, simple and inexpensive genotyping of SNPs related to dose requirements. This information allows the prediction of drug efficiency in patients prior to treatment with acenocoumarol and the prevention of adverse drug reactions.
Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22917719     DOI: 10.1016/j.clinbiochem.2012.08.005

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  2 in total

Review 1.  Use of medication for cardiovascular disease during pregnancy.

Authors:  Petronella G Pieper
Journal:  Nat Rev Cardiol       Date:  2015-12       Impact factor: 32.419

2.  Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.

Authors:  Antonio J Carcas; Alberto M Borobia; Marta Velasco; Francisco Abad-Santos; Manuel Quintana Díaz; Carmen Fernández-Capitán; Nuria Ruiz-Giménez; Olga Madridano; Pilar Llamas Sillero
Journal:  Trials       Date:  2012-12-13       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.